Fenofibric acid for hyperlipidemia

Bibliography

• Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 2002;106(25):3143-421
   PubMed Web of Science ®Google Scholar
• Pearson TA, Blair S, Daniels S, AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update. Circulation 2002;106:388-91
   PubMed Web of Science ®Google Scholar
• Grundy SM, Cleeman JI, Merz CN, Implications of recent clinical trials for the National Cholesterol Education Program adult treatment panel III guidelines. J Am Coll Cardiol 2004;44:720-32
   PubMed Web of Science ®Google Scholar
• Toth PP, Potter D, Ming E. Prevalence of lipid abnormalities in the United States: the National Health and Nutrition Examination Survey 2003 – 2006. Circulation 2010;122:A12055
   Web of Science ®Google Scholar
• Assman G, Cullen P, Schulte H. The Munster Heart Study (procam): results of follow-up at 8 years. Eur Heart J 1998;19:A2-A11
   PubMed Web of Science ®Google Scholar
• Jeppesen J, Hein HO, Suadicani P, Triglyceride concentration and ischemic heart disease- an eight year follow-up in the Copenhagen male study. Circulation 1998;97:1029-36
   PubMed Web of Science ®Google Scholar
• Austin M, Rodriguez B, McKnight B, Low-density lipoprotein particle size, triglycerides, and high-density lipoprotein cholesterol as risk factors for coronary heart disease in older Japanese-Americans Men. Am J Cardiol 2000;86:412-16
   PubMed Web of Science ®Google Scholar
• Preiss D, Sattar N. Lipids. Lipid modifying agents and cardiovascular risk: a review of the evidence. Clin Endocrinol 2009;70:815-28
   PubMed Web of Science ®Google Scholar
• Wierzbicki A. Interpreting clinical trials of diabetic dyslipidaemia: new insights. Diabetes Obes Metab 2009;11:261-70
   PubMed Web of Science ®Google Scholar
• Hokanson JE, Autin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 1996;3(2):213-19
   PubMedGoogle Scholar
• Asia Pacific Cohort Studies Collaboration. Serum triglycerides as a risk factor for cardiovascular diseases in the Asia-Pacific region. Circulation 2004;110:2678-86
   PubMed Web of Science ®Google Scholar
• Avins AL, Newhaus JM. Do triglycerides provide meaningful information about heart disease risk? Arch Intern Med 2000;160:1937-44
   PubMedGoogle Scholar
• Sarwar N, Danesh J, Eiriksdottir G, Triglycerides and the risk of coronary heart disease: 10,1058 incident cases among 262,525 participants in 29 Western prospective studies. Circulation 2007;115:450-8
   PubMed Web of Science ®Google Scholar
• Saha AS, Kizhakepunnur LG, Bahekar A, Arora RR. The role of fibrates in the prevention of cardiovascular disease—a pooled meta-analysis of long-term randomized placebo-controlled clinical trials Am Heart J. 2007;154(5):943-53
   Google Scholar
• Jun M, Foote C, Lv J, Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet 2010;375:1875-84
   PubMed Web of Science ®Google Scholar
• Baigent C, Keech A, Kearney PM, Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-78
   PubMed Web of Science ®Google Scholar
• Milionis HJ, Elisaf MS, Mikhailidis DP. Treatment of dyslipidaemias in patients with established vascular disease: a revival of the fibrates. Curr Med Res Opin 2000;16(1):21-32
   PubMed Web of Science ®Google Scholar
• Jones P, Davidson M, Kashyap M, Efficacy and safety of ABT-335 (fenofibric acid) in combination with rosuvastatin in patients with mixed dyslipidemia: a phase III study. Atherosclerosis 2009;204:208-15
   PubMed Web of Science ®Google Scholar
• Mohiuddin S, Pepine C, Kelly M, Efficacy and safety of ABT-335 (fenofibric acid) in combination with simvastatin in patients with mixed dyslipidemia: a phase III, randomized, controlled study. Am Heart J 2009;157:195-203
   PubMed Web of Science ®Google Scholar
• Goldberg AC, Bays HE, Ballantyne CM, Efficacy and safety of ABT-335 (fenofibric acid) in combination with atorvastatin in patients with mixed dyslipidemia. Am J Cardiol 2009;103(4):515-22
   PubMed Web of Science ®Google Scholar
• Bays HE, Jones PH, Mohiuddin SM, Long-term safety and efficacy of fenofibric acid in combination with statin therapy for the treatment of patients with mixed dyslipidemia. J Clin Lipidol 2008;2(6):426-35
   PubMed Web of Science ®Google Scholar
• Kipnes MS, Roth EM, Rhyne JM, Year two assessment of fenofibric acid and moderate- dose statin combination: a phase III, open-label, extension study. Clin Drug Investig 2010;30(1):51-61
   PubMed Web of Science ®Google Scholar
• Roth EM, Rosenson RS, Carlson DM, A phase III study evaluating the efficacy and safety of 135 mg fenofibric acid (ABT- 335) in combination with 5 mg rosuvastatin in patients with atherogenic dyslipidemia. J Am Coll Cardiol 2009;53(Suppl A):A208
   Google Scholar
• Pepine CJ, Jacobson TA, Carlson DM, Combination rosuvastatin plus fenofibric acid in a cohort of patients 65 years or older with mixed dyslipidemia: subanalysis of two randomized, controlled studies. Clin Cardiol 2010;33(10):609-19
   PubMed Web of Science ®Google Scholar
• Rosenson RS, Carlson DM, Kelly MT, Achievement of lipid targets with the combination of rosuvastatin and fenofibric acid in patients with type 2 diabetes mellitus. Cardiovasc Drugs Ther 2011;25(1):47-57
   PubMed Web of Science ®Google Scholar
• Goldberg AC, Bittner V, Pepine CJ, Efficacy of fenofibric acid plus statins on multiple lipid parameters and its safety in women with mixed dyslipidemia. Am J Cardiol 2011;107:898-905
   PubMed Web of Science ®Google Scholar
• Keech A, Simes RJ, Barter P, Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005;366(9500):1849-61
   PubMed Web of Science ®Google Scholar
• Ginsberg HN, Elam MB, Lovato LC, Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010;362:1563-74
   PubMed Web of Science ®Google Scholar
• Report of the Committee of Principal Investigators. W.H.O. cooperative trial on primary prevention of ischaemic heart disease using clofibrate to lower serum cholesterol: mortality follow-up. Lancet 1980;2(8191):379-85
   PubMed Web of Science ®Google Scholar
• Guivarc'h P-H, Vachon MG, Fordyce D. A new fenofibrate formulation: results of six single dose, clinical studies of bioavailability under fed and fasting conditions. Clin Ther 2004;26(9):1456-69
   PubMed Web of Science ®Google Scholar
• Trilipix (fenofibric acid tablets) [product package insert]. Abbott Laboratories; North Chicago, IL: 2008
   Google Scholar
• Zhu T, Pradhan R, Yan Z, Effect of food on fenofibric acid absorption from ABT-335. Paper presented at: 37th Annual Meeting of the American College of Clinical Pharmacology; 14 – 16 September 2008; Philadelphia, PA
   Google Scholar
• Zhu T, Ansquer JC, Kelly MT, Comparison of the gastrointestinal absorption and bioavailability of Fenofibrate and fenofibric acid in humans. J Clin Pharmacol 2010;50:914-21
   PubMed Web of Science ®Google Scholar
• Zhu T, Awni W, Hosmane B, ABT-335, the choline salt of fenofibric acid, does not have a clinically significant pharmacokinetic interaction with rosuvastatin in humans. J Clin Pharmacol 2009;49:63-71
   PubMed Web of Science ®Google Scholar
• Jones PH, Goldberg AC, Knapp HR, Efficacy and safety of fenofibric acid in combination with atorvastatin and ezetimibe in patients with mixed dyslipidemia. Am Heart J 2010;160:759-66
   PubMed Web of Science ®Google Scholar
• Pierce LR, Wysowski DK, Gross TP. Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy. JAMA 1990;264(1):71
   PubMed Web of Science ®Google Scholar
• Glueck CJ, Oakes N, Speirs J, Gemfibrozil-lovastatin therapy for primary hyperlipoproteinemias. Am J Cardiol 1992;70(1):1
   PubMed Web of Science ®Google Scholar
• Duell PB, Connor WE, Illingworth DR. Rhabdomyolysis after taking atorvastatin with gemfibrozil. Am J Cardiol 1998;81(3):368
   PubMed Web of Science ®Google Scholar
• McKeage K, Keating GM. fenofibrate: a review of its use in dyslipedemia. Drugs 2011;71(14):1917-48
   PubMed Web of Science ®Google Scholar
• Wi J, Kim JY, Park S, Optimal pharmacological approach to patients with hypertriglyceridemia and low high-density lipoprotein-cholesterol. A randomized comparison of fenofibrate 160 mg with niacin 1500 mg. Atherosclerosis 2010;213(1):235-40
   PubMed Web of Science ®Google Scholar
• The AIM-HIGH Investigators. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011;365:2255-67
   PubMed Web of Science ®Google Scholar